Fig. 2.

Ratio between the mean AAD/6W in each subgroup category and the within-arm mean AAD/6W. Subgroup factors presented are ERI category by quartile (a), hs-CRP (b), DM status (c), eGFR (d), primary disease of CKD − CGN (e), DN, NS, and other, concomitant ACEi/ARB use (f), GNRI quintile (g), and PNI quartile (h). CKD, chronic kidney disease; ERI, erythropoiesis-stimulating agent resistance index; DA, darbepoetin alfa; eGFR, estimated glomerular filtration rate; hs-CRP, high-sensitivity C-reactive protein; DM, diabetes mellitus; CGN, chronic glomerular nephritis; DN, diabetic nephropathy; NS, nephrosclerosis; ACEi/ARB, angiotensin-converting enzyme inhibitor/angiotensin receptor blocker; GNRI, geriatric nutritional risk index; PNI, prognostic nutritional index; AAD/6W, average allocated dose of roxadustat or darbepoetin alfa per administration in the last 6 weeks.